Pawel Stocki joined Ossianix in 2015 and, as vice president of research, leads antibody discovery and development programs, including lead characterization, candidate drug nomination and preclinical pharmacodynamic animal studies, primarily in the area of neurodegeneration. Previously, Dr. Stocki worked in the antibody discovery group at MedImmune, focusing on the intracellular delivery of biologics. He also held an industrial position at Psynova Neurotech, a startup from the University of Cambridge and a subsidiary of Myriad Genetics, where he was a team leader responsible for novel target identification, antibody screening and validation. Dr. Stocki holds an MSc in protein biochemistry from the University of Gdansk (Poland) and a PhD in immunology from Newcastle University (UK); he completed postdoctoral studies in cell biology at the University of Toronto (Canada). Throughout his career, Dr. Stocki has coauthored more than thirty peer-reviewed scientific publications, book chapters and patents.